Logo image of NRSN

NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Fundamental Analysis

NASDAQ:NRSN - Nasdaq - IL0011809592 - Common Stock - Currency: USD

1.09  -0.01 (-0.91%)

After market: 1.08 -0.01 (-0.92%)

Fundamental Rating

0

Overall NRSN gets a fundamental rating of 0 out of 10. We evaluated NRSN against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of NRSN have multiple concerns. NRSN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRSN has reported negative net income.
NRSN had a negative operating cash flow in the past year.
In the past 5 years NRSN always reported negative net income.
In the past 5 years NRSN always reported negative operating cash flow.
NRSN Yearly Net Income VS EBIT VS OCF VS FCFNRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

NRSN has a worse Return On Assets (-407.98%) than 97.16% of its industry peers.
Industry RankSector Rank
ROA -407.98%
ROE N/A
ROIC N/A
ROA(3y)-170.91%
ROA(5y)-200.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRSN Yearly ROA, ROE, ROICNRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRSN Yearly Profit, Operating, Gross MarginsNRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

NRSN has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NRSN has been reduced compared to a year ago.
NRSN Yearly Shares OutstandingNRSN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
NRSN Yearly Total Debt VS Total AssetsNRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

NRSN has an Altman-Z score of -41.21. This is a bad value and indicates that NRSN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -41.21, NRSN is doing worse than 93.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -41.21
ROIC/WACCN/A
WACCN/A
NRSN Yearly LT Debt VS Equity VS FCFNRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M

2.3 Liquidity

A Current Ratio of 0.46 indicates that NRSN may have some problems paying its short term obligations.
The Current ratio of NRSN (0.46) is worse than 93.78% of its industry peers.
A Quick Ratio of 0.46 indicates that NRSN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.46, NRSN is doing worse than 93.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.46
NRSN Yearly Current Assets VS Current LiabilitesNRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.17% over the past year.
EPS 1Y (TTM)27.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-210%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.02% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.41%
EPS Next 2Y18.57%
EPS Next 3Y14.02%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRSN Yearly Revenue VS EstimatesNRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026
NRSN Yearly EPS VS EstimatesNRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRSN. In the last year negative earnings were reported.
Also next year NRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRSN Price Earnings VS Forward Price EarningsNRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRSN Per share dataNRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as NRSN's earnings are expected to grow with 14.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.57%
EPS Next 3Y14.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROSENSE THERAPEUTICS LTD

NASDAQ:NRSN (2/21/2025, 8:00:01 PM)

After market: 1.08 -0.01 (-0.92%)

1.09

-0.01 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-18 2024-12-18/dmh
Earnings (Next)03-19 2025-03-19/bmo
Inst Owners2.78%
Inst Owner ChangeN/A
Ins Owners21.31%
Ins Owner ChangeN/A
Market Cap25.32M
Analysts80
Price Target7.65 (601.83%)
Short Float %1.01%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.41%
Min EPS beat(2)-67.38%
Max EPS beat(2)90.2%
EPS beat(4)3
Avg EPS beat(4)46.1%
Min EPS beat(4)-67.38%
Max EPS beat(4)140.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)42.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)17.24%
EPS NY rev (3m)17.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS-0.07
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -407.98%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.91%
ROA(5y)-200.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.46
Quick Ratio 0.46
Altman-Z -41.21
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-210%
EPS Next Y29.41%
EPS Next 2Y18.57%
EPS Next 3Y14.02%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.41%
OCF growth 3YN/A
OCF growth 5YN/A